Features
Do the Advantages of 25-Gauge Vitrectomy Outweigh the Disadvantages?
One surgeon explains why his answer is yes.
The Economics of Visudyne
The latest cost and reimbursement changes were a net positive, but attention to efficiency remains crucial.
Will the AMD Therapies Now in Clinical Trials Deliver What They Promise?
Two specialists discuss the possible impact on practice management and what we still need to know about the new drugs.
New Instruments: Patient-Reported Health Outcomes
Understanding a patient's perception of his quality of life may play an important role in evaluating AMD treatment options.
By SANJAY SHARMA, MD, FRCS, MSC
Reaffirming the Gold Standard
Even with the development of new imaging technology, fluorescein angiography remains a valuable tool for diagnosing and treating AMD.
By MITHLESH SHARMA, MD
Realizing the Potential of OCT
Where does optical coherence tomography fit into AMD treatment decision-making and outcomes assessment? A clinical investigator weighs in.
The ICG Advantage
Indocyanine green angiography comes into its own as a tool for AMD diagnosis and management.
Departments
Insights from Industry
Diabetic Retinopathy: a Formidable Challenge
Intravitreal Injections: A Coding and Reimbursement Review
The number of claims your practice files will increase as new therapeutic substances become available.
Upfront
A New Forum for Retina Specialists